Shots:

• The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis- plaque psoriasis- Crohn's disease- uveitis and ulcerative colitis
• The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety- efficacy- PK- immunogenicity in patients with moderate to severe chronic plaque-type psoriasis
• Hyrimoz (adalimumab) is an inhibitor of tumor necrosis factor (TNF) indicated for rheumatoid arthritis- plaque psoriasis- Crohn's disease and ulcerative colitis-causing inflammation and tissue destruction

Ref: Sandoz | Image: Twitter